In an elderly patient on rivaroxaban who develops a scalp hematoma after a fall with a normal head CT, what is the appropriate management?

Management of Scalp Hematoma in Elderly Patient on Rivaroxaban with Normal Head CT

In an elderly patient on rivaroxaban who develops a scalp hematoma after a fall with a normal head CT, stop rivaroxaban temporarily, provide local therapy and manual compression, and do NOT administer reversal agents such as andexanet alfa or prothrombin complex concentrate (PCC). 1

Classification of Bleeding Severity

This clinical scenario represents a non-major bleed because it does not meet criteria for major bleeding, which requires: 1

• Bleeding at a critical site (intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal)
• Hemodynamic instability
• Hemoglobin decrease ≥2 g/dL or transfusion of ≥2 units RBCs

A scalp hematoma with normal head CT imaging does not qualify as bleeding at a critical site.

Immediate Management Steps

For this non-major bleed on rivaroxaban: 1

• Stop rivaroxaban temporarily
• Provide local therapy/manual compression to the scalp hematoma
• Do NOT administer reversal/hemostatic agents (andexanet alfa or PCC are not indicated for non-major bleeds on DOACs)
• Provide supportive care and volume resuscitation as needed
• Assess for and manage comorbidities that could contribute to bleeding (thrombocytopenia, uremia, liver disease)

Why Reversal Agents Are Not Indicated

The 2020 ACC Expert Consensus explicitly states that if the patient is not on a vitamin K antagonist (VKA), do not administer reversal/hemostatic agents for non-major bleeds. 1 This is critical because:

• Reversal agents (andexanet alfa, PCC) are reserved for major bleeding or life-threatening bleeding 1
• For rivaroxaban specifically, andexanet alfa dosing is based on timing and dose of last rivaroxaban intake, but only indicated for major bleeds 1
• The French guidelines similarly recommend symptomatic treatment without PCC for non-severe bleeding on anti-Xa DOACs 2

Observation and Monitoring Considerations

The normal head CT is reassuring, but consider: 3, 4

• The risk of delayed intracranial hemorrhage in patients on rivaroxaban with negative initial head CT is approximately 0.95% 3
• Patients on DOACs with head trauma have higher rates of intracranial hemorrhage compared to non-anticoagulated patients, but the absolute risk remains low with negative initial imaging 4
• Admission solely for observation may not be necessary if the initial CT is negative and the patient is on rivaroxaban monotherapy (without concurrent antiplatelet therapy) 3

However, clinical judgment should guide observation decisions based on:

• Mechanism and severity of fall
• Patient reliability for follow-up
• Presence of concurrent antiplatelet therapy (which increases bleeding risk) 4

Rivaroxaban Pharmacokinetics

Understanding drug clearance helps guide timing decisions: 1

• Rivaroxaban half-life is 6-15 hours depending on renal function 1
• The terminal elimination half-life is 5-9 hours in healthy adults 5
• In elderly patients with reduced creatinine clearance, the half-life may be prolonged 1, 5
• Rivaroxaban is not dialyzable due to high plasma protein binding 5

When to Restart Anticoagulation

Once the scalp hematoma is stable and hemostasis achieved: 1

Consider restarting rivaroxaban if:

• The source of bleeding has been identified and controlled
• The patient is not at high risk of rebleeding
• There is an ongoing indication for anticoagulation (atrial fibrillation, VTE prophylaxis, etc.)

Delay restarting if: 1

• Patient is at high risk of rebleeding
• Surgical or invasive procedures are planned
• The bleed occurred at a critical site (not applicable here with isolated scalp hematoma)

Common Pitfalls to Avoid

1. Do not reflexively administer reversal agents for non-major bleeds—this exposes patients to unnecessary thrombotic risk (approximately 4-8% thromboembolic event rate with reversal agents) 2, 4, 6

2. Do not assume all head trauma requires admission—with negative CT and rivaroxaban monotherapy, outpatient management with close follow-up may be appropriate 3

3. Do not forget to assess for concurrent antiplatelet use—combination therapy significantly increases bleeding risk and may warrant more aggressive monitoring 1, 4

4. Do not use standard coagulation tests (PT, INR, aPTT) to guide management—these are not reliable for monitoring rivaroxaban effect 5

5. Do not continue rivaroxaban during active bleeding—temporary discontinuation is appropriate even for non-major bleeds 1